Home Jurnale medicale Medicina nucleara, Medicina nucleara
Jurnale medicale
Medicina nucleara

Jurnale medicale Medicina nucleara, Medicina nucleara

6 Februarie 2015 22:00
Cancer stem cells (CSCs) are a subpopulation within a tumor, which possesses the characteristics of self-renewal, differentiation, tumorigenicity, and drug resistance. The aim of this study was to target the colorectal CSC marker CD133 with an131I-labeled specific monoclonal antibody (AC133 mAb) in mai mult
Nuclear Medicine and Biology
6 Februarie 2015 22:00
The myeloperoxidase inhibitor AZD3241, has been selected as a candidate drug currently being developed to delay progression in patients with neurodegenerative brain disorders. Part of the decision tree for translation of AZD3241 into clinical studies included the need for assessment of brain exposur mai mult
Nuclear Medicine and Biology
3 Februarie 2015 22:00
The PET radiotracer [18F]FMISO has been used in the clinic to image hypoxia in tumors. The aim of the present study was to optimize the radiochemical parameters for the preparation of [18F]FMISO using a microfluidic reaction system. The main parameters evaluated were (1) precursor concentration, (2) mai mult
Nuclear Medicine and Biology
3 Februarie 2015 22:00
The C4b binding protein (C4bp) ?/?-chain C-terminal effectively induces polymerization during protein synthesis. Using this fragment and the single-domain antibody EG2, which targets the epidermal growth factor receptor (EGFR), we generated the novel multimeric antibody EG2-C4bp?. We radiolabeled mai mult
Nuclear Medicine and Biology
28 Ianuarie 2015 22:00
Loss of the ability to concentrate 131I is one of the important causes of radioiodine-refractory disease in papillary thyroid carcinoma (PTC). Recent advantages of serum microRNAs (miRNAs) open a new realm of possibilities for noninvasive diagnosis and prognosis of many cancers. The aim of the curre mai mult
Nuclear Medicine and Biology
29 Ianuarie 2015 22:00
We examined whether the amino acid PET tracers, trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) and11C-methyl-l-mehionine (11C-Met), are suitable for detecting early responses to combination therapies including temozolomide (TMZ), interferon-? (IFN), and bevacizumab (Bev) in g mai mult
Nuclear Medicine and Biology
2 Februarie 2015 22:00
We reported the kinetic parameters Km and Vmax of alanine-serine-cysteine transporter 2 (ASCT2)- and sodium-coupled neutral amino acid transporter 2 (SNAT2)-mediated transport of trans-1-amino-3-fluoro-[1-14C]cyclobutanecarboxylic acid ([14C]FACBC), which were calculated based on 4 different experim mai mult
Nuclear Medicine and Biology
26 Ianuarie 2015 22:00
There have been many applications of the peaceful use of the atom. Probably none have been as effective as the radiopharmaceuticals developed to better understand human biology and to improve patient care through diagnosis or radiotherapy [1]. The latter goal is the focus of this review using parall mai mult
Nuclear Medicine and Biology
26 Ianuarie 2015 22:00
The figure 5.A (at 12 h) was recorded mistakenly at 14 h and should be replaced with the new one at 12 h, to achieve its conformity with biodistribution studies. Fortunately no meaningful difference between two images was observed. mai mult
Nuclear Medicine and Biology
5 Ianuarie 2015 22:00
The present review was conceived for describing the differences in biodistribution and diagnostic performance of two types of 18F-radiolabeled choline for positron emission tomography (PET) imaging in prostate cancer (PCa), such as fluoromethylcholine (FCH) and fluoroethylcholine (FEC). mai mult
Nuclear Medicine and Biology
5 Ianuarie 2015 22:00
Both subtypes of sigma (??) receptors, ??1 and ??2, are over-expressed in many cancers with ??2 proposed as a biomarker of tumor proliferation. We are interested in developing a high affinity selective ??2 radioligand for in vivo monitoring of proliferative status of solid tumors and response to ant mai mult
Nuclear Medicine and Biology
5 Ianuarie 2015 22:00
Tc-99m compounds are mainly used in myocardial blood flow studies. These compounds, however, are produced by a generator and alternate single photon emission computed tomography (SPECT) radiopharmaceuticals are therefore required to avoid the risks posed by generator failure. Three radiolabeled comp mai mult
Nuclear Medicine and Biology
6 Ianuarie 2015 22:00
Early detection and/or prediction of metastasis provide more prognostic relevance than local recurrence. Direct spread into the peritoneum is frequently found in pancreatic cancer patients, but positron emission tomography (PET) with 2-deoxy-2-fluoro-d-glucose (FDG) is not useful for identifying suc mai mult
Nuclear Medicine and Biology
7 Ianuarie 2015 22:00
To investigate the factors affecting 18F FDOPA uptake in patients with primary brain tumors (PBT) after treatment. mai mult
Nuclear Medicine and Biology
15 Ianuarie 2015 22:00
A major event for an Editor is the annual Impact Factor report for that Journal. In some institutions, the Impact Factors of the journals in which a scientist publishes their research are a consideration for promotion, as an indicator of the value of an academic program and even of an institution. I mai mult
Nuclear Medicine and Biology
21 Ianuarie 2015 22:00
The scope of using no carrier added (NCA) 90Y [T1/2=64.1h, E?(max)=2.28MeV] obtained from 90Sr/90Y generator in radiation synovectomy (RSV) is widely accepted. In the present study, the prospect of using 90Y produced by (n,?) route in a medium flux research reactor for use RSV was explored. mai mult
Nuclear Medicine and Biology
21 Ianuarie 2015 22:00
188Rhenium-HEDP is an effective bone-targeting therapeutic radiopharmaceutical, for treatment of osteoblastic bone metastases. It is known that the presence of carrier (non-radioactive rhenium as ammonium perrhenate) in the reaction mixture during labeling is a prerequisite for adequate bone affinit mai mult
Nuclear Medicine and Biology
22 Ianuarie 2015 22:00
Rodent models are extensively used to assess the biochemical and physiological changes associated with aging. They play a major role in the development of therapies for age-related pathologies such as Parkinson's disease. To validate the usefulness of these animal models in aging or age-related dise mai mult
Nuclear Medicine and Biology
28 Decembrie 2014 22:00
18F HX4 is a 2-nitroimidazole based investigational radiotracer for imaging hypoxia mai mult
Nuclear Medicine and Biology
31 Ianuarie 2015 22:00
31 Ianuarie 2015 22:00
25 Decembrie 2014 22:00
The functions of I2-imidazoline receptors (I2Rs) are unknown, but evidence exists for their involvement in various neuropsychiatric disorders. Although a few positron emission tomography (PET) I2R ligands have been developed, of which [11C]FTIMD and [11C]BU99008 were evaluated as PET I2R imaging lig mai mult
Nuclear Medicine and Biology
22 Decembrie 2014 22:00
18F]FMISO, the widely used positron emission tomography (PET) hypoxia tracer, is a chiral compound clinically used as a racemic mixture. The purpose of this study was to synthesize the individual (R)- and the (S)- enantiomers of [18FFMISO and compare their PET imaging characteristics mai mult
Nuclear Medicine and Biology
19 Decembrie 2014 22:00
The use of ?-emitting isotopes for radionuclide therapy is a promising treatment strategy for small micro-metastatic disease. The radioisotope 213Bi is a nuclide that has found substantial use for targeted ?-therapy (TAT). The relatively unexplored aqueous chemistry of Bi3+, however, hinders the d mai mult
Nuclear Medicine and Biology
19 Decembrie 2014 22:00
[125I]Iodo-ASEM, a new radioligand with high affinity and selectivity for ?7-nAChRs (Ki=0.5 nM; ?7 / ?4?2=3,414), has been synthesized in radiochemical yield of 33?6% from the corresponding di-butyltriazene derivative and at high specific radioactivity (1,600Ci/mmol; 59.2MBq/?mol). [125I]Iodo- mai mult
Nuclear Medicine and Biology
19 Decembrie 2014 22:00
Peptide receptor radionuclide therapy (PRRT) is a treatment option for both iodine-refractory differentiated and advanced medullary thyroid cancer (TC). It requires over-expression of somatostatin receptor subtype II (SSTR) that can be non-invasively assessed by positron emission tomography (PET). A mai mult
Nuclear Medicine and Biology
19 Decembrie 2014 22:00
Overexpression of gastrin-releasing peptide receptors (GRPR) has been reported in several cancers. Bombesin (BN) analogs are short peptides with a high affinity for GRPR. Different BN analogs were evaluated for radionuclide imaging and therapy of GRPR-expressing tumors. We have previously investigat mai mult
Nuclear Medicine and Biology
21 Decembrie 2014 22:00
Human tumors xenografted in immunodeficient mice are crucial models in nuclear medicine to evaluate the effectiveness of candidate diagnostic and therapeutic compounds. However, little attention has been focused on the biological profile of the host model and its potential effects on the bio-distrib mai mult
Nuclear Medicine and Biology
21 Decembrie 2014 22:00
The heavy halogen 211At is of great interest for targeted radiotherapy because it decays by the emission of short-range, high-energy ?-particles. However, many astatine compounds that have been synthesized are unstable in vivo, providing motivation for seeking other 211At labeling strategies. One r mai mult
Nuclear Medicine and Biology
31 Decembrie 2014 22:00
.
1 - 30 din 4981
paginamedicala.ro utilizeaza fisiere de tip cookie pentru a personaliza si imbunatati experienta ta pe website-ul nostru. Prin click pe butonul "Accepta" accepti utilizarea modulelor cookie. Daca ai nevoie de mai multe detalii despre cum functioneaza acestea, citeste Politica de confidentialitate